Sector: Healthcare | Industry: Pharmaceuticals |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 951 Yamato Road, Suite 220 BOCA RATON FL 33431 |
Tel: | N/A |
Website: | https://www.therapeuticsmd.com |
IR: | See website |
Key People | ||
Thomas G. Thompson Executive Chairman of the Board | Marlan D. Walker Chief Executive Officer | Joseph Ziegler Principal Financial Officer, Principal Accounting Officer |
Business Overview |
TherapeuticsMD, Inc. is a healthcare company. The Company is focused on developing and commercializing products exclusively for women. It is engaged in conducting business by out-licensing its products and collecting royalties, after granting a license to commercialize the Company's IMVEXXY, BIJUVA, and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands in the United States and its possessions and territories and assigning the Company's exclusive license to commercialize ANNOVERA in the United States and its possessions and territories to Mayne Pharma. ANNOVERA is a one-year (13 cycles) ring-shaped contraceptive vaginal system (CVS)). ANNOVERA, which is made with a silicone elastomer, contains segesterone acetate, a 19-nor progesterone derivative also known as Nestorone (SA) and ethinyl estradiol (EE). Its menopause portfolio includes IMVEXXY and BIJUV. IMVEXXY (estradiol vaginal inserts) for the treatment of moderate-to-severe dyspareunia. |
Financial Overview |
For the fiscal year ended 31 December 2023, TherapeuticsMD Inc revenues decreased 98% to $1.3M. Net loss before extraordinary items totaled $7.7M vs. income of $1.1M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Net loss reflects Selling and marketing increase from $0K to $8.9M (expense). |
Employees: | 1 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $17.12M as of Dec 31, 2023 |
Annual revenue (TTM): | $1.30M as of Dec 31, 2023 |
EBITDA (TTM): | -$7.54M as of Dec 31, 2023 |
Net annual income (TTM): | -$7.70M as of Dec 31, 2023 |
Free cash flow (TTM): | -$48.14M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 11,532,443 as of Mar 27, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |